EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy

Siamak Daneshmand iD, Clint Cary iD, Timothy Masterson, Lawrence Einhorn, Nabil Adra iD, Stephen A Boorjian, Christian Kollmannsberger iD, Anne Schuckman, Alan So, Peter Black iD, Aditya Bagrodia iD, Eila Skinner und 10 weitere

Journal of Clinical Oncology · 01.06.2023 · 41 (16) · 3009-3018

DOI: 10.1200/jco.22.00624 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2023. Verfasst von Siamak Daneshmand und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Testicular Neoplasms, Seminoma, Neoplasms, Germ Cell and Embryonal, Lymphadenopathy. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The long-term toxicities of chemotherapy and radiotherapy can represent a significant burden to testicular cancer survivors. Retroperitoneal lymph node dissection (RPLND) is an established treatment for testicular germ cell tumors with minimal late morbidity although little data exist on its efficacy in early metastatic seminoma. Surgery in early metastatic seminoma is a prospective phase II single-arm, multi-institutional trial of RPLND as first-line treatment for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. PATIENTS AND METHODS Twelve sites in the United States and Canada prospectively enrolled adult patients with testicular seminoma and isolated retroperitoneal lymphadenopathy (1-3 cm). Open RPLND was performed by certified surgeons with a primary end point of 2-year recurrence-free survival (RFS). Complication rates, pathologic up/downstaging, recurrence patterns, adjuvant therapies, and treatment-free survival were assessed. RESULTS A total of 55 patients were enrolled, with a median (IQR) largest clinical lymph node size of 1.6 cm (1.3-1.9). RPLND pathology demonstrated a median (IQR) largest lymph node size of 2.3 cm (0.9-3.5); nine patients (16%) were pN0, 12 (22%) pN1, 31 (56%) pN2, and 3 (5%) pN3. One patient received adjuvant chemotherapy. With a median (IQR) follow-up of 33 months (12.0-61.6), 12 patients experienced recurrence, with a 2-year RFS of 81% and a recurrence rate of 22%. Of the patients who experienced recurrence, 10 were treated with chemotherapy and two underwent additional surgery. At last follow-up, all patients who experienced a recurrence were disease-free and the 2-year overall survival was 100%. Four patients (7%) experienced short-term complications, and four patients experienced long-term complications including incisional hernia (1) and anejaculation (3). CONCLUSION RPLND is a treatment option for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy and is associated with low long-term morbidity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsSeminomaNeoplasms, Germ Cell and EmbryonalLymphadenopathyMaleAdultHumansProspective StudiesRetroperitoneal SpaceLymph Node ExcisionRetrospective StudiesNeoplasm Staging

Autor:innen und Institutionen

  • Department of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Department of Urology, Indiana University, Indianapolis, IN.
  • Division of Hematology & Medical Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Urology, Mayo Clinic, Rochester, MN.
  • Division of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
  • Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Siamak Daneshmand, Clint Cary, Nabil Adra, Christian Kollmannsberger, Peter Black, Aditya Bagrodia, Scott Eggener, Phillip Pierorazio, Kelly Stratton, Lucia Nappi, Craig Nichols

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Daneshmand, S., Cary, C., Masterson, T., Einhorn, L., Adra, N., Boorjian, S. A., Kollmannsberger, C., Schuckman, A., So, A., Black, P., Bagrodia, A., Skinner, E., Alemozaffar, M., Brand, T., Eggener, S., Pierorazio, P., Stratton, K., Nappi, L., Nichols, C., …, & Hu, B. (2023). Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. Journal of Clinical Oncology, 41(16), 3009-3018. https://doi.org/10.1200/jco.22.00624

Vancouver

Daneshmand S, Cary C, Masterson T, Einhorn L, Adra N, Boorjian SA, et al. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy. Journal of Clinical Oncology. 2023;41(16):3009-3018. doi:10.1200/jco.22.00624

BibTeX
@article{Daneshmand2023,
  author = {Daneshmand, Siamak and Cary, Clint and Masterson, Timothy and Einhorn, Lawrence and Adra, Nabil and Boorjian, Stephen A and Kollmannsberger, Christian and Schuckman, Anne and So, Alan and Black, Peter and Bagrodia, Aditya and Skinner, Eila and Alemozaffar, Mehrdad and Brand, Timothy and Eggener, Scott and Pierorazio, Phillip and Stratton, Kelly and Nappi, Lucia and Nichols, Craig and Luo, Chunqiao and Li, Ming and Hu, Brian},
  title = {Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {16},
  pages = {3009--3018},
  doi = {10.1200/jco.22.00624}
}
Kostenlos starten →